SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CytoDyn Inc. (CYDY) trades at a trailing P/E of 187.6. Trailing earnings yield is 0.53%.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 187.6); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.53%).
- Trailing Earnings Yield 0.53% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 30/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CYDY
Valuation Multiples
P/E (TTM)187.6
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield0.53%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.27 |
$0.00 |
$-25.7M |
- |
| 2017 |
$-0.19 |
$0.00 |
$-25.76M |
- |
| 2018 |
$-0.28 |
$0.00 |
$-50.15M |
- |
| 2019 |
$-0.21 |
$0.00 |
$-56.19M |
- |
| 2020 |
$-0.34 |
$0.00 |
$-139.94M |
- |
| 2021 |
$-0.30 |
$0.00 |
$-174.02M |
- |
| 2022 |
$-0.43 |
$266K |
$-210.82M |
-79255.6% |
| 2023 |
$-0.10 |
$0.00 |
$-79.82M |
- |
| 2024 |
$-0.05 |
$0.00 |
$-49.84M |
- |
| 2025 |
$0.00 |
$-5.92M |
$3.75M |
- |
